various infertility issues over the past few
months and got an average success rate
of ~72% which is too good.
“We’re working closely with select
fertility clinics in our target region
to transform them into centre of
excellence using our process and product
innovations,” says R Vijaygopal, Co-
Founder and CEO while adding, “we also
have been collaborating with leading
IT, ITeS & other hi-stress industries
to connect with their employees for
comprehensive assessment of their
holistic reproductive health.”
As of now, the company has limited its
operations only to South and Western
India. While it has been assisting over a
dozen clinics in Karnataka, Tamil Nadu
and Maharashtra to serve their patients
better in a B2B model, the founders
realized that scaling would largely
depending on directly reaching out to the
couples through a B2C platform. Thus,
Vyabl came into being. Vyabl is currently
in the alpha testing phase and the
platform will be open to public by this
month i.e. June 2017. During the next 18
months Vyabl will have 60 centres across
India and 15 across ASEAN, MENA, UK
and USA.
Elaborating on the decision to expand
globally, Vijaygopal mentioned, “The
scope for Vyabl is global. While India
alone can give us commercial viability,
the reason behind choosing to go global
is driven by the need to have transfer of
technology and practices from across the
globe to all Vyabl centres. This will help
PRODUCTS & SOLUTIONS
• Vyabl is a platform
which serves as an
ecosystem for fertility
care from spreading
awareness using
questionnaire through
diagnostics screening
to facilitation of actual
fertility procedures
through aggregation
service.
• ParSight is the clinical
data analytics for
oncology with clinical
decision support,
insights for pharma/
CROs, marketplace for
second opinion, clinical
trial matching system
etc.
• Others - Health I